The opioid crisis is the most important issue facing the nation, yet it’s largely ignored by the mainstream media.
So how do we explain the epidemic’s seemingly inexplicable spike in deaths, deaths that can’t be attributed to opioids?
The answer is in a little-known but growing field of machine injection technology: machine mouldings.
A 2016 study found that the number of overdose deaths from prescription opioid use had tripled since 2013, according to data compiled by the National Institute on Drug Abuse.
The trend accelerated in 2016, when the number was at an all-time high of 14,000 per day.
In 2017, the death toll climbed to nearly 34,000.
Machine injection technology is used to extract pharmaceutical drugs from a substance such as a pharmaceutical drug, or other controlled substance.
They are then injected into a patient’s body, either through the mouth or in a vein.
The drugs are then extracted by a process called “vertical” injection, where the needle is placed in a slot, which then can be opened with a small amount of pressure.
There are now more than 1.4 million such machines in the United States, according a 2016 report by the Center for Drug Policy Policy Research.
The vast majority of them are in the drug industry, according the Center, but some are used by people who are unemployed or who lack the skills to maintain them.
A lot of the time, the machines are set up in public places and are usually operated by a contractor, such as the pharmaceutical company Merck, the National Association of Manufacturers, the American Chemistry Council, and other industry groups.
These groups have been lobbying against government oversight of these machines, claiming they are ineffective, dangerous, and unsafe.
In April, President Donald Trump signed an executive order that requires all federal contractors to ensure that their machines comply with all federal safety standards.
The machines that manufacturers and the companies that set them up are using are not controlled by the FDA, which regulates the drugs.
But the FDA has given the drug companies more than a year to ensure the machines meet the agency’s safety standards, according in a statement.